164 related articles for article (PubMed ID: 37045502)
1. Genetic-Guided Oral P2Y
Ingraham BS; Farkouh ME; Lennon RJ; So D; Goodman SG; Geller N; Bae JH; Jeong MH; Baudhuin LM; Mathew V; Bell MR; Lerman A; Fu YP; Hasan A; Iturriaga E; Tanguay JF; Welsh RC; Rosenberg Y; Bailey K; Rihal C; Pereira NL
JACC Cardiovasc Interv; 2023 Apr; 16(7):816-825. PubMed ID: 37045502
[TBL] [Abstract][Full Text] [Related]
2. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y
Mathew RO; Sidhu MS; Rihal CS; Lennon R; El-Hajjar M; Yager N; Lyubarova R; Abdul-Nour K; Weitz S; O'Cochlain DF; Murthy V; Levisay J; Marzo K; Graham J; Dzavik V; So D; Goodman S; Rosenberg YD; Pereira N; Farkouh ME
Cardiovasc Drugs Ther; 2024 Jun; 38(3):447-457. PubMed ID: 36445624
[TBL] [Abstract][Full Text] [Related]
4. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
5. Implementation of CYP2C19 genotyping and clinical outcomes following percutaneous coronary intervention in East Asian patients treated with oral P2Y
Xi Z; Wang Y; Lu Q; Qiu H; Gao Y; Gao A; Gao R
Thromb Res; 2023 Aug; 228():85-93. PubMed ID: 37301117
[TBL] [Abstract][Full Text] [Related]
6. Net clinical benefit of clopidogrel versus ticagrelor in elderly patients carrying CYP2C19 loss-of-function variants with acute coronary syndrome after percutaneous coronary intervention.
Zhang D; Li P; Qiu M; Liang Z; He J; Li Y; Han Y
Atherosclerosis; 2024 Mar; 390():117395. PubMed ID: 38114408
[TBL] [Abstract][Full Text] [Related]
7. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
[TBL] [Abstract][Full Text] [Related]
8. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
[TBL] [Abstract][Full Text] [Related]
9. A Genotype-Guided Strategy for Oral P2Y
Claassens DMF; Vos GJA; Bergmeijer TO; Hermanides RS; van 't Hof AWJ; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; Asselbergs FW; Mosterd A; Herrman JR; Dewilde WJM; Janssen PWA; Kelder JC; Postma MJ; de Boer A; Boersma C; Deneer VHM; Ten Berg JM
N Engl J Med; 2019 Oct; 381(17):1621-1631. PubMed ID: 31479209
[TBL] [Abstract][Full Text] [Related]
10. The contribution of genotype-guided selection of P2Y
Wu Y; Yu D; Zhang L; Wu Y; Shu B; Ma L; Shi T
Eur J Clin Pharmacol; 2023 Sep; 79(9):1249-1259. PubMed ID: 37449992
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W
Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of P2Y
Thomas CD; Williams AK; Lee CR; Cavallari LH
Pharmacotherapy; 2023 Feb; 43(2):158-175. PubMed ID: 36588476
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes and Sustainability of Using
Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA
Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
[TBL] [Abstract][Full Text] [Related]
15. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
[TBL] [Abstract][Full Text] [Related]
16.
Beitelshees AL; Thomas CD; Empey PE; Stouffer GA; Angiolillo DJ; Franchi F; Tuteja S; Limdi NA; Lee JC; Duarte JD; Kreutz RP; Skaar TC; Coons JC; Giri J; McDonough CW; Rowland R; Stevenson JM; Thai T; Vesely MR; Wellen JT; Johnson JA; Winterstein AG; Cavallari LH; Lee CR;
J Am Heart Assoc; 2022 Feb; 11(4):e024159. PubMed ID: 35156424
[TBL] [Abstract][Full Text] [Related]
17. Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy.
Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Claassens DMF; Ten Berg JM; Asselbergs FW; Al-Ali AK
BMC Cardiovasc Disord; 2020 Jun; 20(1):268. PubMed ID: 32493215
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes.
Dong OM; Friede KA; Chanfreau-Coffinier C; Voora D
Eur Heart J Qual Care Clin Outcomes; 2023 Apr; 9(3):249-257. PubMed ID: 35652783
[TBL] [Abstract][Full Text] [Related]
19. Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation.
Shimamatsu J; Sasaki KI; Katsuki Y; Kawasaki T; Murasato Y; Ajisaka H; Yokoi H; Tashiro H; Harada A; Hirakawa Y; Ishizaki Y; Ishimatsu T; Kagiyama K; Fukumoto Y; Kakuma T; Ueno T
Heart Vessels; 2020 Mar; 35(3):312-322. PubMed ID: 31549178
[TBL] [Abstract][Full Text] [Related]
20. Ticagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic Coronary Syndrome.
Manzo-Silberman S; Guedeney P; Cayla G; Beygui F; Rangé G; Motovska Z; Procopi N; Kerneis M; Zeitouni M; El Kasty M; Teiger E; Filippi E; Coste P; Huchet F; Cottin Y; Karasek J; Arnould MA; Braik N; Barthelemy O; Portal JJ; Vicaut E; Montalescot G; Silvain J;
JACC Cardiovasc Interv; 2024 Jun; 17(12):1413-1421. PubMed ID: 38842993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]